Tesamorelin

Summary

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog and the only peptide in this class with FDA approval — granted in 2010 for HIV-associated lipodystrophy, where two phase 3 trials showed it reduces visceral fat. Outside that indication, human data are limited.

Mechanism

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds GHRH receptors on pituitary somatotrophs, stimulating pulsatile growth hormone release, which raises circulating IGF-1. Elevated GH/IGF-1 signaling promotes lipolysis preferentially in visceral adipose tissue, the effect demonstrated in the HIV lipodystrophy trials.

Reported effects

Ratings are relative to peers in the same category, not absolute claims.

Visceral fat reduction (HIV lipodystrophy)★★★★☆Phase 3 trials showed ~11-15% VAT reduction vs placebo over 26 weeks.

IGF-1 elevation★★★★☆Consistent, dose-dependent rise in IGF-1 reflecting GH axis stimulation.

Body image / subjective outcomes★★☆☆☆Some patients in trials reported improved body image parameters.

Studied dosing — research context

In the published phase 3 trials, 2 mg was injected subcutaneously once daily for 26 weeks (with 26-week safety extensions), and this 2 mg/day dose is the FDA-approved regimen (Egrifta) for HIV-associated lipodystrophy. Studied durations range from 12 to 52 weeks. This describes research protocols, not guidance.

Research context only. This is not a recommendation.

Safety

In trials, the most common adverse events were injection-site reactions (erythema, pruritus, swelling), arthralgia, and myalgia. Worsening blood glucose control occurred more often with tesamorelin than placebo, so glucose monitoring is part of its studied use. As a GH-axis stimulator it is contraindicated in active malignancy. Decades of trial data in HIV-positive adults indicate it is generally well tolerated at studied doses; data in healthy adults are limited.

Limitations